An observational study in Chronic Kidney Disease-Mineral and Bone Disorder, sponsored by Aga Khan University Hospital, Pakistan. Completed. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by Aga Khan University Hospital, Pakistan · Observational
This cross-sectional study was conducted, including those subjects tested for 1,25(OH)2D during Jan 2015-Dec 2021. Estimated glomerular filtration rate (eGFR) was calculated and subjects were classified into chronic kidney disease (CKD) stages. Associations between biochemical marker, calcium, phosphorus, magnesium, alkaline phosphatase, 1,25(OH)2D and CKD stages was determined.
57 studies on the registry are indexed under Chronic Kidney Disease-Mineral and Bone Disorder; 17 are open to participants now.
This study's enrollment of 1,553 is above the median of 174 across 28 observational studies indexed under Chronic Kidney Disease-Mineral and Bone Disorder.
Browse Chronic Kidney Disease-Mineral and Bone Disorder studies →Aga Khan University Hospital, Pakistan is the lead sponsor of 32 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Laboratory data of patients tested for 1,25(OH)2D from January 2015 to December 2021 was retrieved from laboratory integrated systems (ILMS), and only the initial results for 1,25(OH)2D were included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
concentration of serum 1,25 dihydroxy vitamin D in U/L in five stages of chronic kidney disease
In CKD, 1-alfa-hydroxylase activity in the kidneys is reduced, leading to decreases in the level of the activated form of vitamin D (1,25- dihydroxy vitamin D), resulting in secondary hyperparathyroidism and bone disease. This study aimed to determine the concentration of 1,25 dihydroxy vitamin D in different stages of CKD.
Time frame: 7 year
concentration of serum calcium in mg/dl in five stages of chronic kidney disease
in renal tubules, 1,25- dihydroxy vitamin D increase reabsorption of calcium from renal filtrate and thus stabilize blood calcium levels. in CKD, with deterioration of kidney function, stage V, the levels of calcium drops resulting in hypocalcemia.
Time frame: 7 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2015 to primary completion in Dec 2021, 83 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Kidney Disease-Mineral and Bone Disorder →
Aga Khan University Hospital, Pakistan